[
  {
    "ts": null,
    "headline": "Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges",
    "summary": "Investing.com -- Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, expressing concerns over Biogen's near-term revenue mix and the uphill battle in building its Alzheimer’s disease franchise.",
    "url": "https://finnhub.io/api/news?id=e21fa2b179a7816e6c6ec5605d3c52866eeacccf6b6e5ed9095ffdd2f5edacec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735827947,
      "headline": "Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges",
      "id": 132242741,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, expressing concerns over Biogen's near-term revenue mix and the uphill battle in building its Alzheimer’s disease franchise.",
      "url": "https://finnhub.io/api/news?id=e21fa2b179a7816e6c6ec5605d3c52866eeacccf6b6e5ed9095ffdd2f5edacec"
    }
  },
  {
    "ts": null,
    "headline": "INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025",
    "summary": "INmune Bio's XPro shows promising results in Alzheimer's, with Phase 2 data expected in 2025, potential for big pharma interest. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=bc8999ff4d784640f56044fffee39ca79cfd114343de1d0c1866ae64ea740323",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735807968,
      "headline": "INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025",
      "id": 132238619,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1554047481/image_1554047481.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "INmune Bio's XPro shows promising results in Alzheimer's, with Phase 2 data expected in 2025, potential for big pharma interest. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=bc8999ff4d784640f56044fffee39ca79cfd114343de1d0c1866ae64ea740323"
    }
  }
]